Women’s health startups should plan for reimbursement early, as limited research and evidence can make securing coverage difficult, a new report explains. The post The Reimbursement Challenges Hurting Women’s Health Companies, Per Milken Institute appeared first on MedCity News.
Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this metabolic disorder, but Vogenx aims to stand apart by offering patients a different mechanism of action and oral dosing. The post Vogenx IPO Raises $81M for Trial in Metabolic Disease With No…
The bottleneck in AI-enabled real-world data analysis is not computation, model architecture, or training data volume. It is the semantic layer over which the AI is trying to reason – the place where precise clinical meaning lives. The post Better Models Won’t Fix Pharma’s AI Problem — Better Terminology Will appeared first on MedCity News.
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is that not only is this terrible for patient health, it can be more costly in the end. The post The True Cost of Focusing on Cost Instead of Cost-Effectiveness appeared…
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed Americans’ skepticism toward public health experts and President Donald Trump’s executive order on childhood vaccines on CBS News 24/7 and CBS News’ CBS Mornings, respectively, on Aug. 11. On Aug. 10, Gounder discussed the risks and benefits of egg freezing on CBS Mornings. Gounder also…
PatientRightsAdvocate.org sued the American Medical Association this week, arguing the trade group has no valid copyright over the CPT codes that providers must use to bill for care. It follows a public letter Senator Bill Cassidy sent to the AMA last year accusing it of “abus[ing] [its] government-backed monopoly by charging exorbitant fees to anyone…
Venrock led Aligned Marketplace’s Series A round. In total, the company has raised $31 million to date. The post Aligned Marketplace Secures $20M for Advanced Primary Care Marketplace appeared first on MedCity News.
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma. The post Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma appeared first on MedCity News.
Among Risant’s efforts is replicating Kaiser Permanente’s success in getting all primary care groups to adopt similar evidence-based approaches to treating conditions
Most younger professionals entering the workforce have little visibility into interoperability, digital health infrastructure, or healthcare data architecture as career pathways. The post Healthcare Keeps Buying AI. But Nobody’s Building the Workforce to Run It. appeared first on MedCity News.